o rapidly take appropriate precautions for specific patients. The assay not only identifies the pathogen but also includes a broad panel of 10 resistance genes (including mecA, vanA,
KPC and TEM),
enhancing a clinician's ability to choose the appropriate antimicrobial therapy and practice proper antibiotic stewardship. Studies have shown active surveillance to be a valuable component of a quality infection control program that enhances treatment decisions, improves patient care, and reduces costs due to extended length of stay, unnecessary isolation, and nursing time.
The HAI BioDetection CE-IVD kit prepares samples for sequencing from DNA extracted from isolates, colonies, positive blood culture, urine, rectal swabs, and stool. This broad array of sample types makes Pathogenica's assay a strong fit for identifying pathogens associated with enteric diseases, bloodstream infections and respiratory disorders – the key profile for HAIs in the US and EU. Furthermore, the assay requires no pre-culturing for urine, rectal swabs, and stool, enabling a streamlined lab workflow and clinically actionable turnaround (12 hours from DNA extraction to results) for patients affected by urinary tract infections or enteric disorders.
"Culture independent sequencing is a great step forward for clinical applications," said Pathogenica co-founder George Church, Prof. of Genetics at Harvard Medical School. "Pathogenica has delivered a next-generation sequencing diagnostic tool that provides identification and antibiotic resistance information for improved infection control and therapeutic decision making."
"Thought leaders in infection control departments have been enthusiastic about our rapid high resolution test," said Adesokan. "Pathogenica produces clinically superior and actionable results more rapidly after sample collection than other technologies such as MALDI-TOPage: 1 2 3 Related biology technology :1
. Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial2
. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis3
. Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda4
. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome5
. Ekahau Achieves 45% Year-over-Year Revenue Growth and Strong Adoption of Safety Alert Solution in 20126
. Infinata’s BioPharm Insight™ Achieves Record Growth in 20127
. Idem Translations Achieves EN 15038:2006 Certification8
. Idem Translations Achieves ISO 13485:2003 Certification9
. Rafarma Pharmaceuticals, Inc. Achieves Full Certification10
. TriCore Solutions Achieves SAP Gold Partner Status11
. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory